Treatment strategies and safety of rechallenge in the setting of immune checkpoint inhibitors-related myositis: a national multicentre study.
Amandine WeillJulie DelyonVincent DescampsLydia DeschampsMonica DinulescuAlain DupuyPhilippe CélérierCharlee NardinFrançois AubinYannick Le CorreValentine HeidelbergerEve MaubecNausicaa MalissenChristine LongvertLaurent MachetValérie GounantSolenne BrosseauBertille BonniaudGéraldine JeudyDimitri PsimarasLudovic DoucetCéleste LebbeGérard ZalcmanAdèle De MassonBarouyr BaroudjianSarah Leonard-LouisBaptiste HervierFlorence Brunet-Possentinull nullPublished in: Rheumatology (Oxford, England) (2021)
Our data highlight that steroid monotherapy is an effective treatment for typical irM, either with prednisone or with intravenous methylprednisone pulses depending on the severity. The identification of unusual features is important in determining the initial therapeutic strategy. The outcomes of rechallenged patients are in favour of a safe reintroduction of ICI following symptom resolution and creatin kinase (CK) normalization in moderate and severe forms of irM.
Keyphrases
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- protein kinase
- combination therapy
- prognostic factors
- peritoneal dialysis
- electronic health record
- clinical trial
- high dose
- high intensity
- open label
- type diabetes
- interstitial lung disease
- patient reported
- big data
- machine learning
- skeletal muscle
- tyrosine kinase
- artificial intelligence
- study protocol
- deep learning
- bioinformatics analysis
- adipose tissue
- data analysis
- weight loss